Market Research Reports

New drug research raises hope for Rett syndrome treatment Rett Syndrome is a commonly found cause for the genetic conditions in women which lead to intellectual disability. It affects the development of the brain which resulting in progressive inability to use muscles for body movements, eye while developing speaking disabilities. Studies suggest the syndrome is frequently suspected in girls.   Presently, there’s no treatment available that can manage the symptoms or the epileptic and respiratory problems faced in by the Rett syndrome patients. There are a couple of research projects which are partially funded by EU. Recent research on the Rett syndrome market studies if a drug that inhibits a central neuroinflammatory protein (GSK3B) could reverse part of the symptoms. The preclinical model of the disease has been initiated in the research which is conducted in mice since they have the same deficiency of protein 2 as found in human Rett syndrome. Global Re...

Rett Syndrome - Therapeutics Development Latest Pharmaceutical and Healthcare disease pipeline guide  Rett Syndrome - Pipeline Review, H1 2017 , provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape. Summery Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.  Report Highlights ·         The Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome - Pipeline Review, H1 2017, provides comprehensive inf...